# Jubaan

Source: https://onco.cc/companies/jubaan/  
OnCo record `jubaan` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jubaan makes Gixam, an investigational device that photographs the tongue and uses the images to predict whether a person is likely to have bowel polyps that can turn into cancer, or bowel cancer itself. It is being tested as a pre-screening step, including in people whose stool test was negative, and is not approved anywhere.

## Summary

Jubaan Ltd. develops and manufactures the Gixam system, a non-invasive pre-screening device for colorectal adenomas and colorectal cancer that analyses images of the tongue; the company also references the gut microbiome in its materials. The company states that Gixam is not approved in the United States, the EU or any other jurisdiction and is an investigational device in the United States, Israel and Europe. Its registered studies are a completed study predicting adenomatous polyps from tongue images (NCT06305364), a study in a faecal immunochemical test (FIT)-negative population (NCT06612281), a study in the Netherlands with Jubaan GmbH (NCT06688110), a second FIT-negative study of advanced and non-advanced colorectal neoplasia (NCT07623902) and a repeatability and reproducibility study (NCT07894081). Its first registered cancer study, NCT06305364, was posted on ClinicalTrials.gov in March 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Jubaan Ltd.
- HQ: Tirat Carmel
- Type: diagnostics
- Website: https://jubaan.com/

## Notes

- Read on 29 October 2026: jubaan.com, a script-rendered site. The regulatory status statements were read through a page-rendering fetch, and the Israel office address (Tirat Carmel) and a European office in Frankfurt came from the same rendering of the contact page; neither could be confirmed in the raw page source, so the HQ should be treated as unconfirmed.
- Founding year and financing not stated. No accuracy figures are given because no study results were read. Gixam is a single-cancer pre-screening tool, not a multi-cancer test.

## Sources

- Official website: https://jubaan.com/
- ClinicalTrials.gov: tongue-image prediction of adenomatous polyps (NCT06305364): https://clinicaltrials.gov/study/NCT06305364
- ClinicalTrials.gov: Gixam in FIT-negative screening, 2026 (NCT07623902): https://clinicaltrials.gov/study/NCT07623902

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)](https://onco.cc/technologies/colorectal-screening/)
- trials: [Evaluation of Gixam's Performance in a FIT Negative Population](https://onco.cc/trials/nct06612281/)

---
JSON: https://onco.cc/api/v1/entities/jubaan.json